https://orcid.org/0000-0001-5842-8622
References
- Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen, C, Gran, JM, Schanzer, D, Cowling, BJ, et al. Global seasonal influenza-associated mortality collaborator network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018 Mar 31;391(10127):1285–300. doi:10.1016/S0140-6736(17)33293-2.
- World Health Organization. Global pandemic influenza action plan to increase vaccine supply. [accessed 2018 Apr 5]. http://apps.who.int/iris/bitstream/10665/69388/1/WHO_IVB_06.13_eng.pdf2006
- Anh DD, Thiem VD, Anh NTH, Huong VM, Nga NT, Thang TC, Thai, DH, Chien, VC, Holt, R, Wahid, R, et al. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. Vaccine. 2016 Oct 26;34(45):5457–62. doi:10.1016/j.vaccine.2016.08.052.
- Guidance on Clinical Trial of Influenza Vaccine. Ministry of health (Administration of science technology and training). Hanoi (Vietnam); 2013.
- The European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, 1997. [accessed 2018Apr 6]. http://www.ema.europa.eu/docsen_GB/document_library/Scientific_guideline/2009/09/WC50000394.pdf
- Flublok package insert. accessed 2018Apr 10. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM524684.pdf
- Flucelvax quadrivalent prescribing information. [accessed 2018Apr 10]. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM502899.pdf
- Flulaval prescribing information. [accessed 2018 Apr 10]. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM112904.pdf
- [accessed 2018 Apr 12]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM329134.pdf
- [accessed 2018 12 Apr]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM305089.pdf
- [accessed 2018 12 Apr]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM335392.pdf
- Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines. 2015 Jul;3(4):97–108. doi:10.1177/2051013615595595.
- Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard, GD, Rolling, T and Cramer, JP. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine–assessing the immunogenicity and safety in an open label, uncontrolled study. Hum Vaccin Immunother. 2015;11(10):2370–75. doi:10.1080/21645515.2015.1064570.
- Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines. 2017 Jun;16(6):545–64. doi:10.1080/14760584.2017.1324302.
- Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Global Influenza Surveillance Network; 2011. [accessed 2018 Apr 6]. http://apps.who.int/iris/bitstream/10665/44518/1/9789241548090_eng.pdf